(FMS) Fresenius Medical Care - Ratings and Ratios

Fresenius Medical Care AG (NYSE:FMS) is a leading global provider of dialysis and related services for patients with renal diseases. The company operates a vast network of outpatient dialysis clinics worldwide, offering comprehensive treatment options that include laboratory and diagnostic services. It also provides materials, training, and patient support services, such as clinical monitoring and supply delivery to patients homes. In the U.S., Fresenius Medical Care offers dialysis services under contract to hospitals for both end-stage renal disease (ESRD) patients and those with acute kidney failure. The company is a key developer and manufacturer of healthcare products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis solutions, and water treatment systems. Additionally, Fresenius Medical Care develops and distributes renal pharmaceuticals, vascular care services, and other specialized treatments. Its products are sold to dialysis clinics, hospitals, and specialized treatment centers through a combination of local sales forces, independent distributors, and sales agents.

Headquartered in Bad Homburg, Germany, Fresenius Medical Care AG was incorporated in 1996. The company is listed on the NYSE under the ticker symbol FMS and is classified under the Health Care Services sub-industry. With a market capitalization of $14.072 billion USD, Fresenius Medical Care operates globally, serving patients in Germany, the United States, and numerous international markets. Its product portfolio includes hemodialysis concentrates, bloodlines, and acute cardiopulmonary and apheresis products. The company also offers vascular, cardiovascular, endovascular specialty, and ambulatory surgery center services. Fresenius Medical Care’s commitment to innovation and patient care has established it as a leader in the renal therapy sector.